>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
MiR-133靶向表皮生长因子受体抑制肝癌细胞的侵袭和迁移
作者:胡东辉  黄橘村  张建军 
单位:湖北省第三人民医院 中西医结合肝病科, 湖北 武汉 430032
关键词:微小RNR-133 表皮生长因子受体 肝癌 增殖 侵袭 
分类号:R34
出版年·卷·期(页码):2019·38·第六期(1044-1049)
摘要:

目的:探究微小RNR-133(miR-133)对肝癌细胞增殖、侵袭和迁移的影响及其作用机制。方法:采用实时定量PCR检测miR-133在肝癌组织或肝癌细胞中的表达。采用Lipofectamine 2000试剂转染miR-133模拟物和miR-133抑制物,随后采用CCK-8和Transwell实验分析人肝癌细胞系HepG2细胞的增殖、侵袭和迁移能力变化。通过PicTar软件预测miR-133的靶基因,并进一步通过双荧光素酶报告实验验证其结合能力。最后利用蛋白质印迹法检测蛋白表达变化。结果:miR-133在肝癌组织和肝癌细胞中的表达显著降低。miR-133能够抑制HepG2细胞的增殖、迁移及侵袭能力。此外,miR-133能够靶向调控表皮生长因子受体(EGFR)的表达,敲低EGFR防止了miR-133下调对肿瘤细胞增殖、侵袭及迁移能力的促进作用。结论:miR-133通过影响EGFR表达而抑制肝癌细胞的增殖、侵袭及迁移。

Objective: To investigate the effect and mechanism of invasion and migration of miR-133 on hepatocellular carcinoma cells. Methods: Real-time PCR was used to detect the expression of miR-133 in tumor tissues or cells. MiR-133 mimic and inhibitor were transfected with Lipofectamine 2000 reagent, then CCK-8 and Transwell analysis were used to detect the potential of proliferation, invasion and migration of human liver cancer cell line HepG2. The target of miR-133 was predicted by PicTar software and luciferase reporter assay was used to verify the binding ability between them. The level of protein was detected by Western blot experiments. Results: The expression of miR-133 in hepatocellular carcinoma tissues and hepatocellular carcinoma cells decreased significantly. MiR-133 inhibited the proliferation, invasion and migration of HepG2 cells. Moreover, miR-133 targeted and regulated epidermal growth factor receptor (EGFR). EGFR knockdown prevented miR-133 downregulation induced hepatoma carcinoma cells proliferation and invasion. Conclusion: MiR-133 inhibits the proliferation, invasion and migration of hepatocellular carcinoma cells by affecting the expression of EGFR.

参考文献:

[1] EL-SERAG H B.Hepatocellular carcinoma[J].N Engl J Med,2011,365(12):1118-1127.
[2] 蔡林,廖伯年.白花蛇舌草解毒健脾方对原发性肝癌晚期患者肿瘤相关指标及疼痛的影响[J].东南大学学报(医学版),2017,36(1):44-47.
[3] CHOI S S,DIEHL A M.Epithelial-to-mesenchymal transitions in the liver[J].Hepatology,2009,50(6):2007-2013.
[4] VAN ZIJL F,ZULEHNER G,PETZ M,et al.Epithelial-mesenchymal transition in hepatocellular carcinoma[J].Future Oncol,2009,5(8):1169-1179.
[5] FURUTA M,KOZAKI K,TANIMOTO K,et al.The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma[J].PLoS One,2013,8(3):e60155.
[6] HUMMEL R,HUSSEY D J,HAIER J.MicroRNAs:predictors and modifiers of chemo-and radiotherapy in different tumour types[J].Eur J Cancer,2010,46(2):298-311.
[7] DONG Z,ZHONG Z,YANG L,et al.MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9[J].Cancer Lett,2014,343(2):249-257.
[8] NAMLOS H M,MEZA-ZEPEDA L A,BAROY T,et al.Modulation of the osteosarcoma expression phenotype by microRNAs[J].PLoS One,2012,7(10):e48086.
[9] ZHAO G,CAI C,YANG T,et al.MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma[J].PLoS One,2013,8(1):e53906.
[10] TRUINI A,COCO S,ALAMA A,et al.Role of microRNAs in malignant mesothelioma[J].Cell Mol Life Sci,2014,71(15):2865-2878.
[11] ZHAO-QI H,WEI X,JIN-LEI W,et al.MicroRNA-374a protects against myocardial ischemia-reperfusion injury in mice by targeting the MAPK6 pathway[J].Life Sci,2019,232:116619.
[12] YONGCHUN Z,LINWEI T,XICAI W,et al.MicroRNA-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting MYB[J].Cancer Lett,2014,347(1):65-74.
[13] CHENG J,DENG H,XIAO B,et al.piR-823,a novel non-coding small RNA,demonstrates in vitro and in vivo tumor suppressive activity in human gastric cancer cells[J].Cancer Lett,2012,315(1):12-17.
[14] LIU G,JIANG C,LI D,et al.MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer[J].Tumour Biol,2014,35(10):9801-9806.
[15] XIE Z,CAI L,LI R,et al. Down-regulation of miR-489 contributes into NSCLC cell invasion through targeting SUZ12[J].Tumour Biol,2015,36(8):6497-6505.
[16] 郭飞宇,杨军,熊书名,等.表皮生长因子受体和胸苷酸合成酶在原发性肝癌中的表达和意义[J].中华肝脏病杂志,2018,26(9):666-669.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 250588 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364